Pneumococcal disease is a leading cause of childhood morbidity and mortality globally,
causing an estimated 0.7--1.0 million deaths annually among children aged< 5 years. A …

Background: Pneumococcal conjugate vaccines (PCV) are emerging as one of the most
promising means to prevent pediatric disease. The 7-valent PCV (PCV-7) has been …

Several years after the seven-valent pneumococcal conjugate vaccine (PCV7) was
introduced in Canada and elsewhere, routine infant vaccination has led to near eradication …

Seven-valent pneumococcal conjugate vaccine (PCV7) was licensed in February 2000. In
June 2000, the Advisory Committee on Immunization Practices and the American Academy …

Pneumococcal conjugate vaccines (PCVs) have proven to be the best way to prevent severe
childhood pneumococcal disease but until recently have been difficult for many countries to …

The 13-valent pneumococcal conjugate (PCV13, Prevenar 13®, Pfizer Inc., NY, USA) was
developed as a successor to the currently registered 7-valent pneumo coccal conjugate …

Summary Background In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was
licensed and recommended in the USA for prevention of invasive pneumococcal disease in …

The thirteen valent pneumococcal conjugate vaccine (PCV13, Prevenar 13Ô) is the broader
coverage successor to the highly effective seven valent vaccine (PCV7, PrevenarÔ) which …

This article reviews the lessons learned from a decade of experience with PCV7, the
increasing problem of disease due to nonvaccine serotypes, and the likelihood of PCV13 to …

Background There are little data on the immunogenicity of PCV10 and PCV13 in the same
high-risk population. Methods PCV10 and PCV13 were studied head-to-head in a …